Kissei Pharmaceutical Co., Ltd. (TYO: 4547)

Market Cap	165.01B
Revenue (ttm)	81.07B
Net Income (ttm)	10.73B
Shares Out	42.81M
EPS (ttm)	241.69
PE Ratio	15.95
Forward PE	16.39
Dividend	90.00 (2.33%)
Ex-Dividend Date	Mar 28, 2025

Volume	59,200
Average Volume	142,180
Open	3,885.00
Previous Close	3,855.00
Day's Range	3,850.00 - 3,890.00
52-Week Range	3,000.00 - 4,270.00
Beta	-0.04
RSI	49.63
Earnings Date	Feb 3, 2025

About Kissei Pharmaceutical

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Kalogra tablets, for the treatment of ulcerative colitis; Tabuneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Malizeb tablets; Tavaris tablets for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1946
• Employees: 1,779
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4547

Financial Performance

In 2023, Kissei Pharmaceutical's revenue was 75.58 billion, an increase of 11.98% compared to the previous year's 67.49 billion. Earnings were 11.16 billion, an increase of 6.00%.